CORRELATION BETWEEN STANDARDIZED UPTAKE VALUE AND HISTOPATHOLOGY OF OESOPHAGEAL CARCINOMA: A SINGLE CENTER ANALYSIS
Aim: This study aims to evaluate the correlation between oesophageal cancer histopathology and the standardised uptake value (SUV) of the primary lesion on positron emission tomography/computed tomography (PET/CT) scan.
Methods: We reviewed clinical data of consecutive newly diagnosed oesophageal cancer patients who underwent positron emission tomography with 2-deoxy-2-[ uorine-18] uoro-D glucose integrated with CT (18F-FDG PET/CT) between September 2009 and July 2014.
Results: A total of 289 baseline scans were performed in this 55-month period. Of these, 171 (59%) were male. The mean age was 52.6 years (standard deviation ± 12.4 years). On histological review, 214 were squamous cell carcinomas (SCCa) and 75 were adenocarcinomas. Of the SCCa, 15.9% were poorly differentiated, 70.6% were moderately differentiated and 13.5% were well differentiated. Of the adenocarcinomas, 20% were poorly differentiated, 45% were moderately differentiated, 28% were well differentiated and signet ring cell was 7%. Mean maximum SUV (SUVmax) for SCCa was 12.6 ± 5.14 and 10.5 ± 6.2 for adenocarcinomas. In bivariate analysis, being a female was associated with a higher SUV in the primary lesion by 1.66 units (P = 0.011) compared to males. Adenocarcinomas were associated with a lower SUV by 2.14 units (P = 0.004) compared to SCCa. In bivariate analysis, no signi cant correlation was found between the T-stage of the tumour and the SUVmax of the primary tumour (P = 0.339). Multivariate analyses showed no association of the SUV of the primary oesophageal tumour with the degree of differentiation of either SCCa or adenocarcinoma. There was no correlation between the SUVmax of the primary lesion and the presence or activity level of a metastatic focus, whether visceral or nodal.
Conclusion: At our centre, three-fourths of patients with oesophageal carcinoma had squamous cell carcinoma on histology. Adenocarcinoma is associated with a lower SUV compared to SCCa. There is no association between the SUVmax and degree of differentiation of the primary oesophageal cancer.
Key words: Fluorodeoxyglucose, oesophageal adenocarcinoma, oesophageal squamous cell carcinoma, positron emission tomography/computed tomography, standardised uptake value
Available from: http://www.cancer.org. [Last accessed on 2014 Mar 01].
Ahmed WU, Qureshi H, Alam E, et al. Oesophageal carcinoma in Karachi. J Pak Med Assoc 1992;42:135-5.
Zhang Y. Epidemiology of esophageal cancer. World J Gastroenterol 2013;19:5598-606.
Berry MF. Esophageal cancer: Staging system and guidelines for staging and treatment. J Thorac Dis 2014;6:289-97.
Ahn SJ, Park MS, Lee JD, et al. Correlation between 18F- fluorodeoxyglucose positron emission tomography and pathologic differentiation in pancreatic cancer. Ann Nucl Med 2014;28:430-5.
Mu DB, Wang SP, Yang WF, et al. Correlation between FDG PET/CT and the expression of glut 1 and ki-67 antigen in esophageal cancer. Zhonghua Zhong Liu Za Zhi 2007;29:30-3.
Sun M, Li B, Fu Z, et al. Relationship between FDG uptake in primary lesion and clinicopathological characteristics of esophageal carcinoma patients. Exp Ther Med 2013;5: 170-4.
Pan L, Gu P, Huang G, et al. Prognostic signi cance of SUV on PET/CT in patients with esophageal cancer: A systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2009;21:100815.
Feng R, Li MH, Kong L, et al. Correlation between PET-CT 18FDG uptake in primary lesions and clinicopathological parameters in esophageal carcinoma patients. Zhonghua Zhong Liu Za Zhi 2009;31:452-4.
Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998;83:2049-53.
Blot WJ, McLaughlin JK. The changing epidemiology of esophageal cancer. Semin Oncol 1999;26 Suppl 15:2-8.
Ali A, Naseem M, Khan TM. Esophageal cancer in Northern areas of Pakistan. J Ayub Med Coll Abbottabad 2009;21:148-50
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Authors retain copyright and grant the Journal of Cancer & Allied Specialties (JCAS) right-of-first publication. In addition, the work will be simultaneously licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International license. This license allows others to share the work in whole or part (for non-commercial purpose), with an acknowledgement of the work’s authorship and initial publication in JCAS.
Furthermore, authors are free to enter into separate contractual arrangements for the non-exclusive distribution of the journal’s published version of the work, with an acknowledgement of its initial publication in this journal.
Authors are permitted and encouraged to share their work online or in medical or scientific conferences prior to or during submission process.